scholarly journals A Phase I Study of Bi-weekly Docetaxel for Recurrent or Advanced Gastric Cancer Patients Whose Disease Progressed by Prior Chemotherapy

2011 ◽  
Vol 41 (6) ◽  
pp. 747-751 ◽  
Author(s):  
Y. Kimura ◽  
H. Yano ◽  
H. Taniguchi ◽  
T. Iwazawa ◽  
K. Danno ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Phase I Study ◽  
Prior Chemotherapy ◽  
Weekly Docetaxel ◽  
Gastric Cancer Patients

scholarly journals Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis

2017 ◽  
Vol 20 (6) ◽  
pp. 970-977 ◽  
Author(s):  
Hyungwoo Cho ◽  
Min-Hee Ryu ◽  
Kyu-pyo Kim ◽  
Baek-Yeol Ryoo ◽  
Sook Ryun Park ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Peritoneal Metastasis ◽  
Gastric Cancer Patients

Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 139-139
Author(s):  
H. Ishigami ◽  
J. Kitayama ◽  
S. Kaisaki ◽  
H. Yamaguchi ◽  
H. Yamashita ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Dose Level ◽  
Peritoneal Metastasis ◽  
Phase I Study ◽  
Level 1 ◽  
Grade 3 ◽  
Gastric Cancer Patients ◽  
Experienced Grade

139 Background: Intraperitoneal (IP) chemotherapy is promising for the treatment of gastric cancer with peritoneal metastasis. We previously verified the safety and efficacy of IP paclitaxel (PTX) combined with S-1 and intravenous (IV) PTX in phase I and phase II studies (Oncology. 2009; Ann Oncol. 2010). Secondly, we developed a new IP-containing chemotherapy regimen, IV PTX plus IP cisplatin (CDDP) and PTX, for patients who have failed S-1-based chemotherapy. We performed a phase I study to determine the maximum-tolerated dose (MTD) and recommended dose (RD) in gastric cancer patients. Methods: A total of 9 gastric cancer patients were enrolled who had shown progression of peritoneal metastasis after S-1-based chemotherapy. PTX was administered intravenously at a dose of 100 mg/m2 and intraperitoneally over 1 hour with an initial dose of 20 mg/m2 (level 1), stepped up to 30 or 40 mg/m2 depending on observed toxicity. CDDP was subsequently administered intraperitoneally at a dose of 30 mg/m2 over 24 hours after PTX infusion. PTX and CDDP were administered on days 1 and 15 in 4-week cycles. Results: At dose level 1, dose-limiting toxicities (DLTs) were observed in 2 of 3 patients. One patient experienced grade 4 leukopenia, and the other grade 3 vomiting. Because of higher toxicities than anticipated, the initial dose-escalation schedule was abandoned, and the doses of IV PTX and IP CDDP were reduced to 80 mg/m2 and 25 mg/m2, respectively, while keeping the dose of IP PTX at 20 mg/m2 (level 0). At dose level 0, one of the first 3 patients experienced grade 3 nausea, and an additional 3 patients experienced no DLTs. Consequently, the MTD and RD were determined to be dose level 1 and dose level 0, respectively. No patients experienced complications related to the peritoneal access device or IP infusion. Conclusions: Combination chemotherapy of IV PTX plus IP CDDP and PTX was shown to be a safe regimen that should be further explored in clinical trials. No significant financial relationships to disclose.

A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)

2014 ◽  
Vol 75 (2) ◽  
pp. 309-318 ◽  
Author(s):  
Yoon-Koo Kang ◽  
Baek-Yeol Ryoo ◽  
Shinkyo Yoon ◽  
Lin Shen ◽  
Jooyun Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Phase I Study ◽  
Prior Chemotherapy

A Phase I Study of Weekly Docetaxel, 24-Hour Infusion of High-Dose Fluorouracil/Leucovorin and Cisplatin in Patients with Advanced Gastric Cancer

Oncology ◽  
2002 ◽  
Vol 63 (3) ◽  
pp. 239-247 ◽  
Author(s):  
Li-Tzong Chen ◽  
Tsang-Wu Liu ◽  
Chew-Wun Wu ◽  
Tsai-Rong Chung ◽  
Her-Shyong Shiah ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Phase I Study ◽  
High Dose ◽  
Weekly Docetaxel

Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer

2009 ◽  
Vol 66 (2) ◽  
pp. 373-380 ◽  
Author(s):  
Sun Jin Sym ◽  
Min-Hee Ryu ◽  
Hye Jin Kang ◽  
Sung Sook Lee ◽  
Heung-Moon Chang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Combination Chemotherapy ◽  
Phase I Study ◽  
Weekly Docetaxel
Sign in / Sign up

Export Citation Format

Share Document